Liver Immune Tolerance Marker Utilization Study

Status Completed

Clinical Trial Summary

The purpose of this study is to validate and test a tolerance gene expression profile for the identification of operationally tolerant liver transplant recipients, allowing for the successful withdrawal of immunosuppression without rejection in these patients.

Clinical Trial Description

Previous pre-clinical work in the Levy Lab identified a novel biomarker gene set for the identification of tolerance in murine models of rapamycin-induced cardiac tolerance and spontaneous hepatic tolerance. Validation of this gene expression tolerance biomarker in operationally tolerant patients is now required for its implementation in the clinical setting. This proposal intends to validate and test our pre-clinically established tolerance gene expression biomarker in the clinical setting in order to translate our findings into improving the length and quality of life of transplant patients in the clinic. The investigators hypothesize that a distinct gene expression profile expressed in the peripheral blood will identify operationally tolerant liver transplant recipients, allowing for the successful withdrawal of immunosuppression in these patients. Our study aims are: (I) To validate the pre-clinical gene expression profile for the identification of operationally tolerant liver recipients in plasma peripheral blood mononuclear cells (PBMCs) (2) To determine that the gene expression profile in the PBMCs is the same as the intra-graft gene expression profile (3) To demonstrate that liver transplant recipients with the tolerant gene expression profile can be safely weaned off of immunosuppression. This proof of principle study will be conducted in two phases at the Toronto General Hospital (TGH) Phase 1 will address study aims 1 and 2, and phase 2 will address study aim 3. Potential participants will be screened and selected following predefined eligibility criteria. Eligible participants will undergo an informed consent process. The primary goal of this study is to validate the pre-clinical tolerant gene expression profile that will allow for the identification of tolerant liver recipients and for the monitored weaning off immunosuppression in these tolerant patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02541916
Study type	Interventional
Source	University of Toronto
Contact
Status	Completed
Phase	N/A
Start date	April 2015
Completion date	May 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05060991` - Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients	Phase 4
Completed	`NCT02833805` - NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia	Phase 2
Completed	`NCT01252537` - Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia	N/A
Completed	`NCT00621699` - Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects	Phase 1
Completed	`NCT01678937` - Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents	N/A
Completed	`NCT00788021` - Protective Immunity Project 01	N/A
Active, not recruiting	`NCT00166842` - Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets	Phase 4
Recruiting	`NCT05616130` - Pathological Myeloid Activation After Sepsis and Trauma
Completed	`NCT03117192` - Zinc Supplementation on Cellular Immunity in Thalassemia Major	Phase 4
Recruiting	`NCT01568697` - Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
Not yet recruiting	`NCT06024226` - Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC
Not yet recruiting	`NCT04961229` - Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response	Phase 4
Completed	`NCT03139565` - High Dose vs. Standard Influenza Vaccine in Adult SOT	Phase 3
Completed	`NCT02547753` - Dental Extractions Among Renal Transplant Recipients
Completed	`NCT01702207` - Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk	Phase 4
Completed	`NCT00626808` - A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children	Phase 4
Completed	`NCT00419575` - Renal Transplantation With Immune Monitoring	N/A
Completed	`NCT00783380` - Influenza Vaccination in Immunocompromized Patients	Phase 4
Completed	`NCT04835948` - Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
Recruiting	`NCT05043870` - Combined Immunosuppression for Pediatric Crohn's Disease	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Liver Immune Tolerance Marker Utilization Study — LITMUS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms